share_log

亞盛醫藥-B:自願公告 - 亞盛醫藥獲得美國FDA的許可,將開展奧雷巴替尼針對過往接受過治療的慢性髓細胞白血病慢性期(CML-CP)患者的全球註冊3期臨床試驗

ASCENTAGE-B: Voluntary Announcement - Ascentage Pharma Received Clearance from U.S. FDA to Initiate Global Registrational Phase 3 Clinical Trial for Olverembatinib in Previously Treated Patients with Chronic Phase Chronic Myeloid Leukemia (CML-CP)

香港交易所 ·  Feb 13 18:47
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more